Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.71 USD | +1.25% | +1.55% | -7.69% |
May. 02 | Enovis Q1 Shares Fall Following Q1 Results | MT |
May. 02 | Transcript : Enovis Corporation, Q1 2024 Earnings Call, May 02, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.69% | 2.8B | B- | ||
+8.38% | 126B | A- | ||
-6.68% | 10.96B | A- | ||
+1.56% | 8.97B | C | ||
+36.32% | 5.56B | B+ | ||
-21.55% | 4.99B | C | ||
+8.20% | 3.44B | C- | ||
-8.42% | 2.18B | - | - | |
-5.20% | 2.16B | - | ||
-22.89% | 1.82B | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ENOV Stock
- Ratings Enovis Corporation